The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors

Table 4 Arm C (vaccine + IL-2 + GM-CSF): patient profiles, clinical data, and immunological outcomes

Pt	Age	Cancer	Stage on enrollment	# of cycles	Off-study reason	PFS^#(ms)	OS* (ms)	Immune response
Pt	Age	Cancer	Stage on enrollment	# of cycles	Off-study reason	PFS^#(ms)	OS* (ms)	Elispot
								Pre-vaccine	Post-vaccine
1C	40	Rectal	IV	15	PD	26.5	80.4	NA	+
2C	59	Colon	NED	14	Completed	110.2+	110.2+	-	-
3C	58	Lung	III	1	PPS	8	72.8	ND
4C	35	Colon	IV	6	PD	6.9	18.7	-	-
5C	52	Rectal	IV	3	PD	3.2	6.4	-	-
6C	36	Rectal	IV	2	PPS/Lost to follow-up	2+	9.2	ND
7C	75	Colon	IV	1	PD	0.9	5.2	ND
8C	49	Colon	IV	3	PD	3.5	5.5	-	-
9C	42	Colon	IV	3	PD	4	7.6	-	-
10C	48	Colon	IV	2	PD	1.7	4.7	ND
11C	48	Rectal	NED	15	Completed	120.4+	120.4+	-	+
12C	54	Colon	IV	3	PD	3.6	26.6	+	+
13C	57	Colon	NED	3	PD	3.6	9.1	NA
14C	66	Pancreatic	IV	2	PD	2.4	2.8	ND
15C	56	Rectal	NED	4	PD	3.6	28.5	-	+
16C	73	Pancreatic	IV	3	PD	3.6	6.6	-	-
17C	51	Colon	IV	2	PD	1.9	7.9	ND
18C	57	Colon	IV	3	PPS	4.4	9.8	-	-
19C	66	Pancreatic	IV	2	PD	2.1	2.7	ND

#Progression free survival was calculated as time from the date the consent was signed until evidence of disease progression or last follow-up without progression (+). *Overall Survival was calculated as time from consent date until death or last follow-up (+). ND, not done because patient received 2 or less vaccines; NA, sample no available. Immune response was marked as negative (-) or positive (+) as described in the manuscript.
Abbreviations: NED No Evidence of Disease, PD Progression of Disease, PPS Poor Performance Status, SD Stable Disease, PFS Progression Free Survival, OS Overall Survival, ms Months.

ISSN: 1479-5876